Posted on Jan. 14, 2014 in Portfolio Progress

Imperial Innovations portfolio company Oxford Immunotec, which will be presenting this week at the JP Morgan Healthcare Conference in San Francisco, announced today that based on preliminary unaudited financial data, it expects total revenue for the fourth quarter of 2013 will be between $10.1 and $10.5 million. For the fiscal year 2013, it expects total revenue of between $38.6 million and $39.0 million.

  • Preliminary fourth quarter revenue of between $10.1 and $10.5 million, an increase of 91% to 99% over the prior year
  • Preliminary 2013 revenue of between $38.6 and $39.0 million, an increase of 87% to 89% over 2012
  • 2014 Revenues expected to be in the range of $47 to $50 million

Read more

distributed by